PAGE 8/46 \* RCVD AT 6/14/2007 8:59:52 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-5/8 \* DNIS:2738300 \* CSID:650 845 6504 \* DURATION (mm-ss):08-18

**CERTIFICATION BY FACSIMILE** 

RECEIVED CENTRAL FAX CENTER

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1713, Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 to Facsimile No. (571) 273-8300 on the date indicated below.

ILIN 1 4 2007

y: May Blegedam

PATENT Attorney Docket No. GC541-4-C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Group Art Unit: 1713

Davis et al.

Examiner: Robert D. Harlan

Serial No.: 10/629,976

Confirmation No.: 9511

Filed: July 30, 2003

For:

Synthesis and Use of

Glycodendrimer Reagents

## RESPONSE TO FINAL OFFICE ACTION AND ADVISORY ACTION

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Sir:

This paper is submitted in response to the Advisory Action dated February 28, 2007.

Applicants thank the Examiner for the telephonic discussion held on June 13, 2007 relating to the priority claim of the present application to application serial number 09/347,029 (hereinafter '029 application), now patent no. US 6,512,098. During the conversation, Applicants reviewed with the Examiner Applicants' response to the Final Office Action dated February 9, 2007 in which evidence was provided in support of Applicants' right to the priority claim.

In the Final Office Action, the Examiner rejected the pending claims under 35 U.S.C. §102(e) as being anticipated by US patent 6,512,098 (hereinafter '098 patent),